As the largest science research institute in Japan, Riken has an important role in promoting innovation. LSIPR talked to Akihiro Fujita, director of the institute’s research cluster for innovation, about the place of intellectual property in that endeavour.
The first US court decision applying the Myriad decision has landed, and it makes for interesting reading, as Antoinette Konski reports.
Genomic Vision develops genetic screening tests for diagnostics and research. In the aftermath of the Myriad ruling, how can it use IP to develop market share? LSIPR spoke to chief executive Aaron Bensimon to find out.
Ethical considerations plus the ambiguity of the Biotech Directive are factors influencing the patentability of totipotent stem cells, says Andrew Sanderson.
Many of the world’s biggest selling drugs have lost exclusivity in recent years, presenting huge opportunities for generic drugs companies but, as LSIPR finds out, it doesn’t have to be a dead end for the innovators.
New guidelines for the examination of biotechnology inventions in Brazil provide useful support for applicants, as Gabriel Di Blasi and Alexandre Santos explain.
When the US Supreme Court decided in favour of Monsanto in its case against a soybean farmer, it clarified the patent status of certain self-replicating technologies. In Europe, the result would probably have been the same, say Steven Zeman and Heike Vogelsang-Wenke.
Frances Salisbury and Lindsey Woolley look at the complex business of patenting agricultural products in Europe.
In Mexico, it can be tricky to protect data exclusivity, but prospective international agreements may provide a solution, as Jose Trigueros explains.
In the life sciences sector, defending broad patent claims can be a tricky business, says Gordon Wright.